# PATENT COOPERATION TREATY

# **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	<u>-</u>	See Form PCT/IPEA/416
10589-41-228		nth (vaan)	Priority date (day/month/year)
International application No.	International filing date (day/mor	nin/year)	1
PCT/US04/21334 02 July 2004 (02.07.2004) 02 July 2003 (02.07.2003) International Patent Classification (IPC) or national classification and IPC			
	or national classification and if C		
IPC: Please See Continuation Sheet USPC: 435/196,320.1,69.1,325,252.3,1	9;536/23.2,23.5;530/350		
Applicant			
PTC THERAPEUTICS, INC.			
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.			
2. This REPORT consists of	a total of $\frac{1}{2}$ sheets, including t	this cover sheet	•
3. This report is also accomp	anied by ANNEXES, comprisir	ng:	
a. (sent to the applica	nt and to the International Bure	eau) a total of	sheets, as follows:
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).			
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.			
h (sent to the Inter	national Bureau only) a total of	(indicate type	and number of electronic carrier(s))
, containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).			
4. This report contains indica	ations relating to the following i	items:	
	asis of the report		
Box No. II P	riority		
	Non-establishment of opinion with regard to novelty, inventive step and industrial pplicability		
<u></u>	ack of unity of invention		
Box No. V R	easoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
	ertain documents cited		
Box No. VII C	ertain defects in the internation	al application	
Box No. VIII C	Certain observations on the inter	national applica	ation
Date of submission of the demand	Date	e of completion	of this report
31 January 2005 (31.01.2005)		Degember 2007 (	04.12.2007)
Name and mailing address of the IPEA/ US		norized officer	4
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		Jordfu ia M. Ramirez	a faultence for
P.O. Box 1450 Alexandria, Virginia 22313-1450			
Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Telephone No. (571) 272-1600			) 272-1600

Form PCT/IPEA/409 (cover sheet)(April 2005)

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/US04/21334

International application No.

Box No. I Basis of the report
1. With regard to the language, this report is based on:
the international application in the language in which it was filed.
a translation of the international application into, which is the language of a translation furnished for the purposes of:
international search (under Rules 12.3 and 23.1(b))
publication of the international application (under Rule 12.4(a))
international preliminary examination (under Rules 55.2(a) and/or 55.3(a))
2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):
the international application as originally filed/furnished
the description:
pages 1-234 as originally filed/furnished pages* NONE received by this Authority on
pages* NONE received by this Authority on
the claims:
pages 235-249 as originally filed/furnished
pages* NONE as amended (together with any statement) under Article 19
pages* NONE received by this Authority on
pages* NONE received by this Authority on
the drawings:
pages 1-33 as originally filed/furnished  pages* NONE received by this Authority on
pages* NONE received by this Authority on
a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
a sequence listing and/or any related table(s) see suppressions.
3. The amendments have resulted in the cancellation of:
the description, pages NONE
the claims, Nos. NONE
the drawings, sheets/figs NONE
the sequence listing (specify): NONE  any table(s) related to the sequence listing (specify): NONE
4. This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
the description, pages
the claims, Nos.
the drawings, sheets/figs
the sequence listing (specify):
any table(s) related to the sequence listing (specify):
* If item 4 applies, some or all of those sheets may be marked "superseded."

Form PCT/IPEA/409 (Box No. I) (April 2005)

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/US04/21334

International application No.

Box No.	Ш	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
The ques	stions Ily ap	whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be plicable have not been examined in respect of:
	the e	ntire international application
$\boxtimes$	claim	s Nos. <u>1-20.36,37 and 39-90</u>
	beca	ise:
		aid international application, or the said claim Nos relate to the following subject matter which does equire an international preliminary examination (specify):
	the d	escription, claims or drawings (indicate particular elements below) or said claims Nos are so unclear no meaning ful opinion could be formed (specify):
Please Se	mean	claims, or said claims Nos. 1-20,36,37 and 39-90 are so inadequately supported by the description that no ningful opinion could be formed (specify): tinuation Sheet
	no ir	nternational search report has been established for said claims Nos.
	a m	eaningful opinion could not be formed without the sequence listing; the applicant did not, within the scribed time limit:
		furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.
		furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Preliminary Examining Authority in a form and manner acceptable to it.
		pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13ter.1(a) or (b) and 13ter.2.
	not.	eaningful opinion could not be formed without the tables related to the sequence listings; the applicant did within the prescribed time limit, furnish such tables in electronic form complying with the technical airements provided for in Annex C-bis of the Administrative Instructions, and such tables were not ilable to the International Preliminary Examining Authority in a form and manner acceptable to it.
	the con	tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not apply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
	See	Supplemental Box for further details

Form PCT/IPEA/409 (Box No. III) (April 2005)

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

international application 140.	
PCT/US04/21334	

Box No. IV	Lack of unity of invention
1.	Lack of unity of invention  sponse to the invitation to restrict or pay additional fees the applicant has, within the applicable time limit: restricted the claims.  paid additional fees.  paid additional fees under protest, and, where applicable, the protest fee paid additional fees under protest but the applicable protest fee was not paid neither restricted the claims nor paid additional fees  Authority found that the requirement of unity of invention is not complied with and chose, according to Rule, not to invite the applicant to restrict or pay additional fees.  ority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is: piled with.  complied with for the following reasons:  of unity section of the International Search Report (Form PCT/ISA/210).
a	ently, this report has been established in respect of the following parts of the international application:  Il parts  ne parts relating to claims Nos. 21-33

Form PCT/IPEA/409 (Box No. IV) (April 2005)

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/21334

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
1. Statement		
Novelty (N)	Claims 21-23, 30-31	YES
	Claims <u>24-29,32-33</u>	NO
Inventive Step (IS)	Claims <u>21-23</u>	YES
	Claims 24-33	NO
Industrial Applicability (IA)	Claims 21-33	YES
moustrial Approcasting (111)	Claims NONE	NO

2. Citations and Explanations (Rule 70.7)

Claims 24-29 lack novelty under PCT Article 33(2) as being anticipated by Strausberg, R., (GenBank accession number BC019582, 03 January 2002). Strausberg teaches a nucleic acid which is longer than the polynucleotide of SEQ ID NO: 11 that comprises all of SEQ ID NO: 11 except that it contains a segment of 51 nucleotides between nucleotides 907-908 of SEQ ID NO: 11. Strausberg, R. also teaches a vector comprising the nucleic acid (pCMV-SPORT6) and a cell comprising the vector (E. coli DH10B). Claims 24-29 are directed to a nucleic acid which would hybridize under highly stringent conditions to the nucleic acid of SEQ ID NO: 11, vectors comprising the nucleic acid, and host cells comprising the vector. Since the nucleic acid of Strausberg, R. would hybridize to the polynucleotide of SEQ ID NO: 11 under the conditions recited, the teachings of Strausberg, R., anticipate the instant claims as written.

Claims 32-33 lack novelty under PCT Article 33(2) as being anticipated by Strausberg, R., (GenBank accession number AAH19582, 03 January 2002). Strausberg teaches a protein which is longer than the polypeptide of SEQ ID NO: 12 that comprises all of SEQ ID NO: 12 except that it contains a segment of 17 amino acids between residues 303-304 of SEQ ID NO: 12. The polypeptide of Strausberg, R. is encoded by a nucleic acid which comprises all of SEQ ID NO: 11 except that it contains a segment of 51 nucleotides between nucleotides 907-908 of SEQ ID NO: 11 (GenBank accession number BC019582, 03 January 2002). Claims 32-33 are directed to a protein encoded by a nucleic acid which would hybridize under highly stringent conditions to the nucleic acid of SEQ ID NO: 11. Since the polynucleotide encoding the polypeptide of Strausberg, R., would hybridize to the nucleic acid of SEQ ID NO: 11 under the stringent conditions recited, the teachings of Strausberg, R., anticipate the instant claims as written.

Claims 30-31 lack an inventive step under PCT Article 33(3) as being obvious over Strausberg, R., (GenBank accession number BC019582, 03 January 2002). The teachings of Strausberg, R. have bee discussed above. Strausberg does not teach a method to recombinantly produce the polypeptide. Claims 30-31 are directed in part to a method to recombinantly produce a polypeptide encoded by a nucleic acid which would hybridize under highly stringent conditions to the nucleic acid of SEQ ID NO: 11. It would have been obvious to one of ordinary skill in the art to recombinantly produce the polypeptide of Strausberg by transforming a host cell with an expression vector comprising the nucleic acid encoding the polypeptide of Strausberg. One of ordinary skill in the art is motivated to construct such vector, transform a host cell and produce the protein recombinantly for the benefit of producing sufficient amounts of the protein for further characterization in a consistent fashion. There is reasonable expectation of success at recombinantly producing the polypeptide of Strausberg because construction of expression vectors, transformation of host cells with such vectors, and expression of the desired protein in a recombinant host cell are well known and widely used in the art. Therefore, the invention as a whole would have been prima facie obvious over the prior art.

Claims 21-23 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the polynucleotide of SEQ ID NO: 11, the polypeptide of SEQ ID NO: 12, or a polypeptide comprising amino acids 280-330 of SEQ ID NO: 12.

Claims 21-33 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/IPEA/409 (Box No. V) (April 2005)

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

INTERNATI	ONAL PRELIMINARY REPORT ON PATENTABILITY	PCT/US04/21334
Supplemental B	Box Relating to Sequence Listing	
Continuation	of Box No. I, item 2:	
1. With regard invention, t	to any nucleotide and/or amino acid sequence disclosed in the in- his report was established on the basis of:	ternational application and necessary to the claimed
a. type of n	naterial	
$\boxtimes$	a sequence listing	
	table(s) related to the sequence listing	
b. format o	of material	
$\boxtimes$	on paper	
$\boxtimes$	in electronic form	
c. time of f	filing/furnishing	
$\boxtimes$	contained in the international application as filed	
$\boxtimes$	filed together with the international application in electronic form	
	furnished subsequently to this Authority for the purposes of search	ch and/or examination
	received by this Authority as an amendment* on	
file	addition, in the case that more than one version or copy of a seq d or furnished, the required statements that the information in the application as filed or does not go beyond the application as filed,	subsequent or additional copies is identical to that in
3. Additional	comments:	
* If item 4 in "superseded."	Box No. I applies, the listing and/or table(s) related thereto, whic	h form part of the basis of the report, may be marked

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/21334

Supplemental Box	
In case the space in any of the preceding boxes is not sufficient.	
Continuation of:	
Continuation of IPC: C12N 9/16( 2006.01),15/00( 2006.01),5/10( 2006.01),1/20( 2006.01);C12P 21/06( 2006.01);C07H 21/04( 2006.01);C07K 14/00( 2006.01) C12Q 1/44( 2006.01)	
	i

Form PCT/IPEA/409 (Supplemental Box) (April 2005)